Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RMD Stock Forecast 2026-2027
$198.50
Current Price
$28.79B
Market Cap
Buy 9
Hold 8
Sell 1
Wall St Analyst Ratings
Distance to RMD Price Targets
+63.7%
To High Target of $325.00
+18.4%
To Median Target of $235.00
-9.3%
To Low Target of $180.00
RMD Price Momentum
-9.7%
1 Week Change
+1.9%
1 Month Change
-21.9%
1 Year Change
-17.6%
Year-to-Date Change
-32.4%
From 52W High of $293.81
+10.1%
From 52W Low of $180.27
📊 TOP ANALYST CALLS
Did RMD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if ResMed is one of their latest high-conviction picks.
Latest RMD Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, RMD has a neutral consensus with a median price target of $235.00 (ranging from $180.00 to $325.00). The overall analyst rating is Buy (7.6/10). Currently trading at $198.50, the median forecast implies a 18.4% upside. This outlook is supported by 9 Buy, 8 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RMD Analyst Ratings
9
Buy
8
Hold
1
Sell
RMD Price Target Range
Low
$180.00
Average
$235.00
High
$325.00
Current: $198.50
Latest RMD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RMD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 10, 2026 | Jefferies | Matthew Taylor | Hold | Maintains | $225.00 |
| Jul 8, 2026 | RBC Capital | Craig Wong-Pan | Outperform | Maintains | $276.00 |
| Jul 8, 2026 | Wells Fargo | Nathan Treybeck | Equal-Weight | Maintains | $225.00 |
| Jun 22, 2026 | Keybanc | Overweight | Maintains | $N/A | |
| Jun 17, 2026 | Morgan Stanley | Equal-Weight | Downgrade | $N/A | |
| Jun 15, 2026 | Citigroup | Buy | Maintains | $N/A | |
| May 1, 2026 | RBC Capital | Outperform | Maintains | $N/A | |
| May 1, 2026 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Apr 27, 2026 | Keybanc | Overweight | Maintains | $N/A | |
| Apr 15, 2026 | JP Morgan | David Low | Overweight | Reinstates | $N/A |
| Apr 9, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Feb 2, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Jan 30, 2026 | RBC Capital | Outperform | Maintains | $N/A | |
| Jan 30, 2026 | Piper Sandler | Neutral | Maintains | $N/A | |
| Jan 30, 2026 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Jan 30, 2026 | Stifel | Hold | Maintains | $N/A | |
| Dec 18, 2025 | Stifel | Hold | Maintains | $N/A | |
| Dec 16, 2025 | Baird | Neutral | Downgrade | $N/A | |
| Nov 3, 2025 | Baird | Outperform | Maintains | $N/A | |
| Oct 31, 2025 | RBC Capital | Outperform | Maintains | $N/A |
ResMed Inc. (RMD) Competitors
The following stocks are similar to ResMed based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ResMed Inc. (RMD) Financial Data
ResMed Inc. has a market capitalization of $28.79B with a P/E ratio of 19.6x. The company generates $5.54B in trailing twelve-month revenue with a 27.4% profit margin.
Revenue growth is +10.8% quarter-over-quarter, while maintaining an operating margin of +35.3% and return on equity of +25.2%.
Valuation Metrics
Market Cap
$28.79B
Enterprise Value
$28.76B
P/E Ratio
19.6x
PEG Ratio
2.0x
Price/Sales
5.3x
Growth & Margins
Revenue Growth (YoY)
+10.8%
Gross Margin
+62.2%
Operating Margin
+35.3%
Net Margin
+27.4%
EPS Growth
+9.2%
Financial Health
Cash/Price Ratio
+5.8%
Current Ratio
3.0x
Debt/Equity
13.0x
ROE
+25.2%
ROA
+14.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
ResMed Inc. (RMD) Business Model
About ResMed Inc.
What They Do
Develops digital health technologies for respiratory care.
Business Model
ResMed generates revenue by selling cloud-connected medical devices and related accessories for the treatment of respiratory conditions like sleep apnea and COPD. The company also offers software and data platforms that enhance therapy monitoring and management for clinicians and patients, creating ongoing service opportunities.
Additional Information
Headquartered in San Diego, California, ResMed has a significant market presence in the Americas, Europe, Japan, and Australia. The company is positioned in the medical instruments and supplies market, merging traditional device therapy with innovative digital care solutions.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
10,600
CEO
Mr. Michael J. Farrell BE, MBA, SM
Country
United States
IPO Year
1995
Website
www.resmed.comResMed Inc. (RMD) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Resmed Divests MatrixCare Business to Sharpen Focus on Connected Care
RMD's MatrixCare sale sharpens its focus on sleep, breathing and connected care while freeing resources for AI-powered digital health.
Jul 10, 2026
By Zacks Equity Research
Analyst Blog
Why ResMed (RMD) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Jul 08, 2026
By Zacks Equity Research
Tale of the Tape
Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report?
ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Jul 07, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Zacks Earnings ESP can help investors identify stocks likely to exceed quarterly earnings estimates more easily.
Why It Matters
The Zacks Earnings ESP tool enhances the likelihood of identifying stocks poised for earnings surprises, potentially leading to better investment decisions and returns.
Source: Zacks Investment Research
Market Sentiment:
Positive
ResMed Analyst Backs Portfolio Reset
5 days ago
Quick Summary
ResMed Inc. (NYSE:RMD) has agreed to sell its MatrixCare business to Frazier Healthcare Partners for $490 million.
Why It Matters
ResMed's sale of MatrixCare for $490 million indicates a strategic shift, potentially improving its focus on core operations and freeing up capital for growth or debt reduction, impacting future valuations.
Source: Benzinga
Market Sentiment:
Neutral
Quick Summary
Zacks Premium offers Style Scores to help investors—value, growth, or momentum—identify strong stocks more easily.
Why It Matters
The Zacks Style Scores can enhance stock selection across investment strategies, potentially leading to better returns and informed decision-making for investors.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
RMD sold its MatrixCare unit to concentrate on sleep, breathing, and connected care, reallocating resources towards AI-driven digital health initiatives.
Why It Matters
RMD's MatrixCare sale reallocates resources to high-growth areas like AI in healthcare, signaling potential for innovation and improved profitability, which may boost investor confidence.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
A curated group of 50 high-quality dividend growth stocks returned 8.69% YTD, underperforming SPY and SCHD. Currently, 39 stocks have a forward return estimate of at least 10%, with 22 potentially undervalued.
Why It Matters
The performance of the curated dividend growth stocks relative to benchmarks indicates potential investment opportunities, especially in undervalued stocks with strong return estimates.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
ResMed will sell its MatrixCare software business to Frazier Healthcare Partners for $490 million, focusing more on sleep, breathing, and home care sectors.
Why It Matters
ResMed's sale of MatrixCare indicates a strategic shift to concentrate on core areas, potentially improving profitability and shareholder value through streamlined operations.
Source: Reuters
Market Sentiment:
Positive
Frequently Asked Questions About RMD Stock
What is ResMed Inc.'s (RMD) stock forecast for 2027?
Based on our analysis of 5 Wall Street analysts, ResMed Inc. (RMD) has a median price target of $235.00. The highest price target is $325.00 and the lowest is $180.00.
Is RMD stock a good investment in 2027?
According to current analyst ratings, RMD has 9 Buy ratings, 8 Hold ratings, and 1 Sell ratings. The stock is currently trading at $198.50. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RMD stock?
Wall Street analysts predict RMD stock could reach $235.00 in the next 12 months. This represents a 18.4% increase from the current price of $198.50. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is ResMed Inc.'s business model?
ResMed generates revenue by selling cloud-connected medical devices and related accessories for the treatment of respiratory conditions like sleep apnea and COPD. The company also offers software and data platforms that enhance therapy monitoring and management for clinicians and patients, creating ongoing service opportunities.
What is the highest forecasted price for RMD ResMed Inc.?
The highest price target for RMD is $325.00 from at , which represents a 63.7% increase from the current price of $198.50.
What is the lowest forecasted price for RMD ResMed Inc.?
The lowest price target for RMD is $180.00 from at , which represents a -9.3% decrease from the current price of $198.50.
What is the overall RMD consensus from analysts for ResMed Inc.?
The overall analyst consensus for RMD is neutral. Out of 5 Wall Street analysts, 9 rate it as Buy, 8 as Hold, and 1 as Sell, with a median price target of $235.00.
How accurate are RMD stock price projections?
Stock price projections, including those for ResMed Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 14, 2026 3:07 PM UTC